family with sequence similarity 169 member AGenealiases: SLAP · SLAP75
Q-omics provides the consensus-scored FAM169A profile across patient tissues and cancer cell-line models. FAM169A expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, FAM169A is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, FAM169A RNA expression shows 19,609 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight MESO, KIRC, and THYM as cancer lineages where FAM169A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM169A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM169A survival associations across molecular data types. FAM169A RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM169A RNA expression–survival associations across cancer types. High FAM169A expression shows unfavorable associations in MESO, HNSC, ACC and KIRP, but favorable associations in KIRC and ESCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for FAM169A RNA expression.
This table summarizes FAM169A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for FAM169A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM169A shows lower tumor expression in KIRC, KIRP and THCA and higher tumor expression in HNSC, COAD and LUAD. The KIRC box plot shows higher FAM169A RNA expression in normal versus tumor tissue (log2 FC = −2.399, t-test p < 0.001).
This table shows molecular features associated with FAM169A in patient tissues and cancer cell lines. In patient samples, FAM169A shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM169A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and BLOOD_Leukemia.
